<DOC>
	<DOCNO>NCT00246610</DOCNO>
	<brief_summary>This study evaluation safety 625 mg formulation administer HIV-infected pregnant woman second trimester six week postpartum . The study also evaluate pharmacokinetics VIRACEPT</brief_summary>
	<brief_title>Safety Of VIRACEPTÂ® 625mg Administered To HIV-Infected Women During Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>HIV infection Second trimester pregnancy Major current prior history obstetrical complication Serious current medical disease Evidence HIV virus resistance antiretroviral agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Non-randomized open-label single-arm study Nelfinavir plus Combivir pregnant female infect HIV-1 virus .</keyword>
</DOC>